Odronextamab 是一种稳定的人源化 IgG4 的 CD20 × CD3 双特异性抗体，可结合 T 细胞上的 CD3 和 B 细胞上的 CD20，触发抗肿瘤作用，Odronextamab 有望用于抗肿瘤领域研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-CD20 & CD3 Reference Antibody (Odronextamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-CD20 & CD3 Reference Antibody (Odronextamab) is 97.48%, determined by SEC-HPLC.

Odronextamab bound to CD20 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Odronextamab bound human CD20-VLP, and the EC50 was 0.1964 nM.

Odronextamab bound to Raji cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE), and test by flow cytometry. As shown in fig, Odronextamab bound to Raji cells, and the EC50 was 17.3 nM.

Odronextamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Odronextamab bound to huCD3e-jurkat cells, and the EC50 was 26.520 nM.

Co-incubation of Odronextab with Jurkat cells, then with the addition of Raji cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Odronextamab was able to activate the NF-AT signaling pathway.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.